Table 3.
Week 24 |
||||||
---|---|---|---|---|---|---|
Week 0 | + | − | Missing | |||
Placebo | PN | + | 18 | 9 (75.0%) | 3 (25.0%) | 6 |
− | 8 | 2 (28.6%) | 5 (71.4%) | 1 | ||
Missing | 2 | 1 | 0 | 1 | ||
Total n | 28 | 12 (57.9%) | 8 (42.1%) | 8 | ||
SPN | + | 9 | 3 (60.0%) | 2 (40.0%) | 4 | |
− | 17 | 2 (14.3%) | 12 (85.7%) | 3 | ||
Missing | 2 | 1 | 0 | 1 | ||
Total n | 28 | 6 (26.3%) | 14 (73.7%) | 8 | ||
VCV | PN | + | 54 | 34 (82.9%) | 7 (17.1%) | 13 |
− | 33 | 10 (34.5%) | 19 (65.5%) | 4 | ||
Missing | 3 | 0 | 0 | 3 | ||
Total n | 90 | 44 (62.9%) | 26 (37.1%) | 20 | ||
SPN | + | 35 | 21 (77.8%) | 6 (22.2%) | 8 | |
− | 53 | 3 (6.3%) | 45 (93.7%) | 5 | ||
Missing | 2 | 0 | 0 | 2 | ||
Total n | 90 | 24 (32.0%) | 51 (68.0%) | 15 |
Note: PN = peripheral neuropathy; SPN = symptomatic neuropathy; VCV = vicriviroc.